Atomoxetine and DAW2020 oral capsules for Obstructive Sleep Apnea

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Obstructive Sleep ApneaAtomoxetine Oral Capsule [Strattera] - Drug
Eligibility
21 - 70
All Sexes
What conditions do you have?
Select

Study Summary

This trial suggests that DAW2020 could be a viable treatment option for OSA patients when used in conjunction with atomoxetine.

Eligible Conditions
  • Obstructive Sleep Apnea

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

1 Primary · 2 Secondary · Reporting Duration: 1 week

1 week
Effect of atomoxetine and DAW2020 on OSA severity
Effect of atomoxetine and DAW2020 on arousal index
Atomoxetine

Trial Safety

Safety Progress

1 of 3

Trial Design

2 Treatment Groups

Atomoxetine and DAW2020 oral capsules
1 of 2
Placebo oral capsules
1 of 2

Active Control

Non-Treatment Group

18 Total Participants · 2 Treatment Groups

Primary Treatment: Atomoxetine and DAW2020 oral capsules · Has Placebo Group · Phase 1 & 2

Atomoxetine and DAW2020 oral capsules
Drug
ActiveComparator Group · 1 Intervention: Atomoxetine Oral Capsule [Strattera] · Intervention Types: Drug
Placebo oral capsules
Drug
PlaceboComparator Group · 1 Intervention: Placebo oral capsule · Intervention Types: Drug

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: 1 week

Who is running the clinical trial?

Brigham and Women's HospitalLead Sponsor
1,480 Previous Clinical Trials
9,735,807 Total Patients Enrolled

Eligibility Criteria

Age 21 - 70 · All Participants · 1 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:

Who else is applying?

What state do they live in?
Massachusetts100.0%
How old are they?
18 - 65100.0%
What site did they apply to?
Brigham and Women's Hospital100.0%
What portion of applicants met pre-screening criteria?
Met criteria100.0%